[The efficacy of switch therapy in community-acquired pneumonia in Japan].
To evaluate the efficacy of Switch therapy for community-acquired pneumonia, we conducted a prospective randomized controlled study in thirty-two hospitalized patients. These cases corresponded to Fine's risk classes II to IV. Using a table of random numbers, sixteen patients were assigned to a Switch therapy group, and the other sixteen, to a clinical pathway group. Both groups initially received intravenous antimicrobials. Within the Switch therapy group, when all the patients were afebrile for more than sixteen hours, their intravenous antimicrobials were switched to oral, and the patients were discharged on the following day. For all patients in the clinical pathway group, the critical pathway was defined as an eight-day planned hospitalization, with a time-task matrix formatted for disease treatment, laboratory testing, physical examination, oxygen saturation monitoring, ambulation, diet, patient education and clinical outcome. Switch therapy reduced the period of intravenous antimicrobial administration from 7.6 days to 4.0 days (p < 0.0001). The period required to switch to oral antimicrobials decreased from 8.3 days to 4.8 days (p < 0.0001); hospital stay length, from 9.8 days to 6.5 days (p = 0.0001); and medical resource utilization, from 330, 373 to 227,768 Japanese yen (p = 0.0002). No patient from either group required readmission. In conclusion, Switch therapy was more efficient than management with a clinical pathway for mild to moderate community-acquired pneumonia in hospitalized patients.
Uchiyama
N
N
Department of Respiratory Disease, St. Luke's Hospital, Tokyo 9-1 Akashi-cho, Chuo-ku, Tokyo, 104-8560, Japan.
Aoshima
M
M
Satoh
T
T
Chonabayashi
N
N
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D017714:Community-Acquired Infections / Q000628:therapy*; D019091:Critical Pathways / Q000191:economics; D004917:Erythromycin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007902:Length of Stay / Q000191:economics; D008297:Male; D008875:Middle Aged; D008911:Minocycline / Q000008:administration & dosage; D011014:Pneumonia / Q000628:therapy*; D011446:Prospective Studies
D000900:Anti-Bacterial Agents; D004917:Erythromycin; D008911:Minocycline